MG
CRNX icon

Mather Group’s Crinetics Pharmaceuticals CRNX Stock Holding History

Mather Group’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-90
Closed -$3.75K – 858
2025
Q3 		$3.75K Buy
+90
New +$2.88K ﹤0.01% 1449
2025
Q2 		– Sell
-70
Closed -$2.35K – 847
2025
Q1 		$2.35K Buy
+70
New +$2.61K ﹤0.01% 1547

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Mather Group's CRNX Position: Q4 2025 in Review

Mather Group sold out of Crinetics Pharmaceuticals (CRNX) in Q4 2025, closing a stake of 90 shares — an estimated $3.75K sold.

Mather Group first reported a position in CRNX in Q1 2025 and held it in 2 quarters. The position peaked at $3.75K in Q3 2025. 240 funds tracked by Wall St. Rank hold CRNX as of Q4 2025.

  • Mather Group reported no remaining Crinetics Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Mather Group sold 90 Crinetics Pharmaceuticals shares in Q4 2025, an estimated $3.75K.
  • Mather Group first reported a position in Crinetics Pharmaceuticals in Q1 2025 and held it in 2 quarters.
  • Mather Group's Crinetics Pharmaceuticals position peaked at $3.75K in Q3 2025.
  • 240 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q4 2025.

Based on Mather Group's 13F filing for Q4 2025, filed 13 Jan 2026.